More than 30,000 Americans are challenged to breathe daily by a condition that doesn’t get the attention it deserves: cystic fibrosis.
Most patients with cystic fibrosis are just wrapping up an annual hassle of the new year – that of confirming their insurance will still cover the medications they need. It’s a process known as insurance reauthorization.
During the pandemic, people with cystic fibrosis weren’t just fighting their disease. Many were also fighting economic uncertainty.
Doctors told my parents I probably wouldn’t live past my 10th birthday. I was born with a rare disease called cystic fibrosis – a genetic disorder affecting the lungs, pancreas and other organs. Thanks to breakthrough medicine, I’m proud to say I recently celebrated my 43rd birthday.
Elated. Nervous. Hopeful. That’s how thousands of cystic fibrosis patients felt upon hearing last week’s news: the Food and Drug Administration will soon review a new triple combination therapy that could drastically improve their quality of life.